XOMA Royalty (XOMA) Research & Development (2011 - 2026)
XOMA Royalty (XOMA) reported Research & Development of $49000.0 for Q1 2026, down 96.21% on a YoY basis from $1.3 million in Q1 2025, and down 82.56% sequentially from $281000.0 in Q4 2025.
XOMA Royalty (XOMA) Research & Development (2011 - 2026) Analysis & Trends
XOMA Royalty (XOMA) has 16 years of Research & Development data on file, last reported at $49000.0 in Q1 2026.
- For the quarter ending Q1 2026, Research & Development fell 96.21% year-over-year to $49000.0; the trailing twelve-month figure through Mar 2026 stood at $1.7 million (down 59.08% YoY), and the FY2025 full-year result was $1.7 million, down 40.45% from the prior year.
- Research & Development declined to $49000.0 in Q1 2026, from $281000.0 in the prior quarter.
- In the past five years, Research & Development ranged from a high of $1.3 million in Q1 2025 to a low of $25000.0 in Q3 2023.
- A 5-year average of $303937.5 and a median of $51500.0 in 2023 frame the typical range for Research & Development.
- Across the five-year window, Research & Development soared 3818.18% in 2025 and tumbled 96.21% in 2026, its largest moves.
- Tracing XOMA's Research & Development over 5 years: stood at $28000.0 in 2022, then decreased by 10.71% to $25000.0 in 2023, then soared by 3356.0% to $864000.0 in 2024, then sank by 67.48% to $281000.0 in 2025, then sank by 82.56% to $49000.0 in 2026.
- Business Quant data shows XOMA's Research & Development at $49000.0 in Q1 2026, $281000.0 in Q4 2025, and $69000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 1.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 541.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | -443.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 343.97 Mn |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - | 49,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49,000.00 |
| Dec 31, 2025 | 281,000.00 |
| Jun 30, 2025 | 69,000.00 |
| Mar 31, 2025 | 1.29 Mn |
| Dec 31, 2024 | 864,000.00 |
| Sep 30, 2024 | 817,000.00 |
| Jun 30, 2024 | 1.16 Mn |
| Mar 31, 2024 | 33,000.00 |
| Dec 31, 2023 | 25,000.00 |
| Sep 30, 2023 | 25,000.00 |
| Jun 30, 2023 | 39,000.00 |
| Mar 31, 2023 | 54,000.00 |
| Dec 31, 2022 | 28,000.00 |
| Sep 30, 2022 | 29,000.00 |
| Jun 30, 2022 | 40,000.00 |
| Mar 31, 2022 | 56,000.00 |
| Dec 31, 2021 | 42,000.00 |
| Sep 30, 2021 | 30,000.00 |
| Jun 30, 2021 | 38,000.00 |
| Mar 31, 2021 | 61,000.00 |